Key facts
- Omniox’s last known valuation is $150.0M (Nov 2023).
- It has raised $119.7M across 5 recorded rounds; the latest was Seed Round ($4.7M) in Jul 2016.
- Notable investors include Plug and Play Tech Center, National Institutes of Health, University of California, Samsara BioCapital, Casdin Capital — 18 tracked in total.
- Omniox has filed 4 Form Ds with the SEC since 2012, most recently Jul 2016 ($4.7M sold to 29 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 5 rounds
- ·The complete investor list — 18 names
- ·Watchlist + deal alerts for Omniox
Funding rounds
5 roundsAbout Omniox
Developer of novel biologics designed to provide meaningful therapeutic benefits to patients. The company's biologics are engineered to deliver oxygen safely to hypoxic tissues, where abnormally low oxygen levels drive disease pathology and worsen patient outcomes by specifically oxygenating pathologically hypoxic tissues they restore normal tissue function with the potential for improved outcomes and patient cures, enabling healthcare professionals to pioneer innovative oxygen-based therapies that restore health to patients.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2006
- Employees
- 3
- Website
- omniox.com/
- Ownership
- Privately Held (backing)
Omniox doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Omniox shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Omniox in its N-PORT filings yet. We sweep new filings monthly.